Clinical Trials Logo

Mental Retardation clinical trials

View clinical trials related to Mental Retardation.

Filter by:

NCT ID: NCT05442229 Not yet recruiting - Clinical trials for Autism Spectrum Disorder

A Cross-sectional Study to Evaluate Speech and Language Development in Chinese Children Aged 2-6 Years

Start date: July 1, 2022
Phase:
Study type: Observational

The purpose of this study is to establish a new Chinese children's speech and language norm by obtaining the latest data of speech and language development of children aged 2 ~ 6 from different regions in China. At the same time, the overall development level and group differences of speech and language in Chinese children aged 2 to 6 years, and the influencing factors of speech and language development in Chinese children aged 2 to 6 years were also discussed.

NCT ID: NCT03847753 Completed - Stroke Clinical Trials

Exploring the Comorbidity Between Mental Disorders and General Medical Conditions

COMO-GMC
Start date: January 1, 2000
Phase:
Study type: Observational [Patient Registry]

Mental disorders have been shown to be associated with a number of general medical conditions (also referred to as somatic or physical conditions). The investigators aim to undertake a comprehensive study of comorbidity among those with treated mental disorders, by using high-quality Danish registers to provide age- and sex-specific pairwise estimates between the ten groups of mental disorders and nine groups of general medical conditions. The investigators will examine the association between all 90 possible pairs of prior mental disorders and later GMC categories using the Danish national registers. Depending on whether individuals are diagnosed with a specific mental disorder, the investigators will estimate the risk of receiving a later diagnosis within a specific GMC category, between the start of follow-up (January 1, 2000) or at the earliest age at which a person might develop the mental disorder, whichever comes later. Follow-up will be terminated at onset of the GMC, death, emigration from Denmark, or December 31, 2016, whichever came first. Additionally for dyslipidemia, follow-up will be ended if a diagnosis of ischemic heart disease was received. A "wash-out" period will be employed in the five years before follow-up started (1995-1999), to identify and exclude prevalent cases from the analysis. Individuals with the GMC of interest before the observation period will be considered prevalent cases and excluded from the analyses (i.e. prevalent cases were "washed-out"). When estimating the risk of a specific GMC, the investigators will consider all individuals to be exposed or unexposed to the each mental disorder depending on whether a diagnosis is received before the end of follow-up. Persons will be considered unexposed to a mental disorder until the date of the first diagnosis, and exposed thereafter.

NCT ID: NCT03651245 Terminated - Deafness Clinical Trials

European Alpha-Mannosidosis Participant

EUMAP
Start date: August 20, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal monitoring study to investigate the prevalence of Alpha-Mannosidosis in participants at risk for Alpha-Mannosidosis.

NCT ID: NCT03503955 Recruiting - Mental Retardation Clinical Trials

Effectiveness of Video Based Games on Upper Extremity Functions in Mild Mental Retardation Diagnosed Cases

Start date: December 13, 2017
Phase: N/A
Study type: Interventional

With Leap Motion Controller, virtual reality exercises have been implemented more often since 2014, and this technology has benefited more from upper extremity rehabilitation In literature, there are no publications investigating the effectiveness of virtual reality applications on upper extremity functions in cases of mental retardation with Leap Motion. We think that virtual reality applications with Leap Motion are effective in fine motor skills and grip strength in cases of mental retardation. The purpose of our work; To Investigation of the Effectiveness of Video Based Games on Upper Extremity Functions in Mild Mental Retardation Diagnosed Cases

NCT ID: NCT02943304 Completed - Mental Retardation Clinical Trials

Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero

ZENI
Start date: May 1, 2016
Phase:
Study type: Observational

This prospective cohort study will determine the natural history of fetal exposure to Zika virus (ZIKV) and its effects on the fetus and newborn with emphasis on neurodevelopment outcome. Exposure of the fetus will be determined by maternal symptomatology, RT-PCR ZIKV (blood and urine) and serologic test specific for ZIKV. Neonates will be classified according to trimester of infection and as exposed and unexposed to ZIKV.

NCT ID: NCT02797418 Terminated - Mental Retardation Clinical Trials

"Cognitus & Moi": a New Cognitive Remediation Tool

COGNITUS
Start date: September 14, 2016
Phase: N/A
Study type: Interventional

Holders children with intellectual disabilities have great difficulty in adapting to social situations and relationships.Cognitive impairment associated with intellectual disability are important factors to understand their difficulties in processing social information. In the field of recognition of facial emotions in particular, basic cognitive processes such as visuospatial and attentional functions, are heavily involved.Cognitive remediation is a management tool widely used by practitioners to help patients who experience cognitive difficulties. Currently, no program can meet specific and validated the problems are children with intellectual disabilities manner in their daily functioning.

NCT ID: NCT02791321 Completed - Clinical trials for Autism Spectrum Disorder

Fragility Assessment in Adults With ADHD and Mental Retardation

EFAAR
Start date: September 23, 2016
Phase: N/A
Study type: Interventional

Frailty is a age dependent physiological state of vulnerability. Frailty is screened by the phenotypic model (5 clinical criteria) or the cumulative model (various clinical and biological criteria). Currently, aging with autism spectrum disorder and mental retardation (ADS-MR) is poor described. Nevertheless many data indicate that people with ADS-MR may present an early aging. Principal aim of this study is to determine if frailty in people with ADS-MR aged over 20 years depend on age. Secondary aims are to evaluate frailty prevalence, to describe with details health according to age, and to verify the frailty index validity for predicting falls, hospitalisation and death, in this population of ADS-MR patients aged over 20 years. This monocentric and prospective study will include 60 ADS-MR patients aged over 20 years and living in Languedoc-Roussillon's medico-social care homes. Patients are evaluated at the time of inclusion. Frailty index is calculated from 104 clinical and biological criteria. Furthermore the investigator staff collect data about ADS severity (CARS), adaptative and intellectual functionning (Vineland), and psychiatric and somatic comorbidities (Reiss scale, DSQIID and CIRS). Falls, hospitalisations or death occurrence is then collected every year during 5 years. The connection between frailty index and age will be studied using linear regression. The frailty index validity will be analysed using ROC curves. Modelisation of the falls, hospitalisations or death risk in the 5 years after the initial evaluation will help in identification of the more frailty predictive criteria.

NCT ID: NCT02298686 Withdrawn - Developmental Delay Clinical Trials

Biomarker for Sanfilippo Type A-B-C-D Disease (BioSanfilippo)

BioSanfilippo
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of Sanfilippo Disease Type A-B-C-D from blood (plasma)

NCT ID: NCT02298647 Withdrawn - Seizures Clinical Trials

Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

BioGM1/BioGM2
Start date: August 20, 2018
Phase:
Study type: Observational

Development of a new MS-based biomarker for the ear-ly and sensitive diagnosis of GM1/GM2 from blood

NCT ID: NCT02245724 Withdrawn - Mental Retardation Clinical Trials

Stem Cell Therapy in Mental Retardation

Start date: September 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study was to analyze the benefit of autologous mononuclear cell therapy in mental retardation.